• Publications
  • Influence
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.
The immune reactivity of allogeneic lymphocytes plays a major role in the control of leukemia after bone marrow transplantation. In patients with recurrent leukemia after marrow transplantation,Expand
  • 1,969
  • 48
  • PDF
Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.
BACKGROUND Promising results of cord-blood transplants from unrelated donors have been reported in adults. METHODS We compared outcomes in 682 adults with acute leukemia who received aExpand
  • 1,049
  • 34
Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia.
In order to compare the outcomes of unrelated umbilical cord blood transplants (UCBTs) or bone marrow transplants, 541 children with acute leukemia (AL) transplanted with umbilical cord blood (n =Expand
  • 730
  • 32
  • PDF
Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow
BACKGROUND Transplantation of blood or bone-marrow stem cells is the treatment of choice for selected patients with chronic myeloid leukaemia (CML). Transplantation is used with increasing frequencyExpand
  • 266
  • 22
Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group.
BACKGROUND Cord-blood banks have increased the use of cord-blood transplantation in patients with hematologic disorders. We have established a registry containing information on the outcome ofExpand
  • 481
  • 17
Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis.
BACKGROUND Umbilical-cord blood (UCB) is increasingly considered as an alternative to peripheral blood progenitor cells (PBPCs) or bone marrow, especially when an HLA-matched adult unrelated donor isExpand
  • 446
  • 15
  • PDF
Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation
Summary Background Transplantation of blood or bone-marrow stem cells is the treatment of choice for selected patients with chronic myeloid leukaemia (CML). Transplantation is used with increasingExpand
  • 567
  • 13
Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group.
We have analyzed factors influencing the outcome of 102 children with acute leukemia given a cord blood transplantation (CBT) and reported to the Eurocord Registry. Seventy patients with acuteExpand
  • 333
  • 10
Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia.
Thirty-two patients with refractory acute myeloid leukemia (AML) received salvage therapy with a single course of mitoxantrone 6 mg/m2 intravenous (IV) bolus, etoposide 80 mg/m2 IV for a period of 1Expand
  • 137
  • 8
Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: a study on behalf of the European Group for Blood and Marrow Transplantation.
Allogeneic stem cell transplantation is the only treatment that can restore a normal hematopoiesis in Fanconi anemia (FA). In this retrospective multicenter study, we analyzed the results of thisExpand
  • 171
  • 8